O. Barysheva, K. E. Egorova, A.M. Golubeva, T.V. Kuprina, N. Vezikova, I. M. Marusenko, T.V. Varlamova, D. D. Varlamova
{"title":"治疗炎症性肠病患者时遇到的困难","authors":"O. Barysheva, K. E. Egorova, A.M. Golubeva, T.V. Kuprina, N. Vezikova, I. M. Marusenko, T.V. Varlamova, D. D. Varlamova","doi":"10.33978/2307-3586-2023-19-35-74-78","DOIUrl":null,"url":null,"abstract":"Inflammatory bowel diseases (IBD) belong to nosologies, adequate treatment of which makes it possible to achieve clinical and endoscopic remission of diseases. Currently, numerous studies have been conducted confirming the effectiveness of genetically engineered biological drugs (GEBD) in ulcerative colitis and Crohn's disease in adult patients and in children. However, GEBDs are not always effective, there is the primary inefficiency, and due to the formation of neutralizing antibodies, secondary inefficiency may develop, as well as drug intolerance. There is a question of choosing a GEBD for a particular patient. The article presents the clinical case of a young patient with ulcerative colitis and breast cancer, discusses the features of the course and approaches to the treatment of ulcerative colitis, as well as the choice of GEBD, the comorbidity of IBD and oncological diseases.","PeriodicalId":11400,"journal":{"name":"Effective Pharmacotherapy","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Difficulties in Treating a Patient with Inflammatory Bowel Disease\",\"authors\":\"O. Barysheva, K. E. Egorova, A.M. Golubeva, T.V. Kuprina, N. Vezikova, I. M. Marusenko, T.V. Varlamova, D. D. Varlamova\",\"doi\":\"10.33978/2307-3586-2023-19-35-74-78\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Inflammatory bowel diseases (IBD) belong to nosologies, adequate treatment of which makes it possible to achieve clinical and endoscopic remission of diseases. Currently, numerous studies have been conducted confirming the effectiveness of genetically engineered biological drugs (GEBD) in ulcerative colitis and Crohn's disease in adult patients and in children. However, GEBDs are not always effective, there is the primary inefficiency, and due to the formation of neutralizing antibodies, secondary inefficiency may develop, as well as drug intolerance. There is a question of choosing a GEBD for a particular patient. The article presents the clinical case of a young patient with ulcerative colitis and breast cancer, discusses the features of the course and approaches to the treatment of ulcerative colitis, as well as the choice of GEBD, the comorbidity of IBD and oncological diseases.\",\"PeriodicalId\":11400,\"journal\":{\"name\":\"Effective Pharmacotherapy\",\"volume\":\"17 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Effective Pharmacotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33978/2307-3586-2023-19-35-74-78\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Effective Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33978/2307-3586-2023-19-35-74-78","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Difficulties in Treating a Patient with Inflammatory Bowel Disease
Inflammatory bowel diseases (IBD) belong to nosologies, adequate treatment of which makes it possible to achieve clinical and endoscopic remission of diseases. Currently, numerous studies have been conducted confirming the effectiveness of genetically engineered biological drugs (GEBD) in ulcerative colitis and Crohn's disease in adult patients and in children. However, GEBDs are not always effective, there is the primary inefficiency, and due to the formation of neutralizing antibodies, secondary inefficiency may develop, as well as drug intolerance. There is a question of choosing a GEBD for a particular patient. The article presents the clinical case of a young patient with ulcerative colitis and breast cancer, discusses the features of the course and approaches to the treatment of ulcerative colitis, as well as the choice of GEBD, the comorbidity of IBD and oncological diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
